Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome
Wed, 14 May 2025 13:14:00 GMT IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon”) (Nasdaq: ELDN) today reported its first quarter 2025 operating and financial results and reviewed recent ...
Mon, 12 May 2025 17:00:00 GMT “We were pleased to report ... Fourth Quarter of 2024 -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel ...
Wed, 07 May 2025 07:45:00 GMT Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology designed to optimize drug delivery for applications with significant unmet need, ...
Wed, 07 May 2025 04:13:00 GMT NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That ...
Mon, 28 Apr 2025 17:00:00 GMT Reports Net Revenues ... 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the ...
